肠道菌群代谢物的失调在动脉粥样硬化（atherosclerosis，AS）患者中广泛存在，且与AS的发展密切相关。中药活性成分在治疗AS方面展现出独特优势，可通过重塑肠道微环境和调节肠道菌群代谢物来发挥抗AS活性。以肠道菌群代谢物为靶点，探索中医药治疗手段与AS之间的科学相关性，有望成为一种前景广阔的AS治疗新途径。通过系统阐明肠道菌群代谢物与AS发生发展的相关性，及中药活性成分调控肠道菌群代谢产物改善AS的药理活性及作用机制，为中医防治AS提供新视角和药物开发新策略。

The imbalance of intestinal flora metabolites is widely present in patients with atherosclerosis (AS) and is closely related to the development of AS. The active ingredients of traditional Chinese medicine (TCM) show unique advantages in treatment of AS, which can exert anti-AS activity by reshaping the intestinal microenvironment and regulating the metabolites of gut microbiota. Taking the metabolites of gut microbiota as the target, exploring the scientific correlation between TCM treatment and AS is expected to become a new way of AS treatment with broad prospects. By systematically elucidating the correlation between gut microbiota metabolites and the occurrence and development of AS, and the pharmacological activity and mechanism of TCM active components regulating gut microbiota metabolites to improve AS, it provides a new perspective and new drug development strategy for the prevention and treatment of AS in TCM.

R285

黑龙江省自然科学基金项目（PL2024H239）